Correlation
The correlation between RPRX and GILD is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
RPRX vs. GILD
Compare and contrast key facts about Royalty Pharma plc (RPRX) and Gilead Sciences, Inc. (GILD).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RPRX or GILD.
Performance
RPRX vs. GILD - Performance Comparison
Loading data...
Key characteristics
RPRX:
1.17
GILD:
2.89
RPRX:
1.83
GILD:
3.88
RPRX:
1.24
GILD:
1.49
RPRX:
0.55
GILD:
2.65
RPRX:
4.50
GILD:
14.34
RPRX:
6.01%
GILD:
5.48%
RPRX:
24.41%
GILD:
27.30%
RPRX:
-49.68%
GILD:
-70.82%
RPRX:
-30.95%
GILD:
-5.59%
Fundamentals
RPRX:
$18.35B
GILD:
$138.21B
RPRX:
$2.47
GILD:
$4.71
RPRX:
13.31
GILD:
23.37
RPRX:
2.92
GILD:
0.23
RPRX:
8.11
GILD:
4.81
RPRX:
2.06
GILD:
7.15
RPRX:
$2.26B
GILD:
$28.73B
RPRX:
$2.26B
GILD:
$22.50B
RPRX:
$2.33B
GILD:
$10.58B
Returns By Period
In the year-to-date period, RPRX achieves a 30.61% return, which is significantly higher than GILD's 20.01% return.
RPRX
30.61%
1.91%
24.98%
23.51%
-4.75%
N/A
N/A
GILD
20.01%
6.62%
20.74%
77.71%
24.03%
11.60%
3.14%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
RPRX vs. GILD — Risk-Adjusted Performance Rank
RPRX
GILD
RPRX vs. GILD - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and Gilead Sciences, Inc. (GILD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
RPRX vs. GILD - Dividend Comparison
RPRX's dividend yield for the trailing twelve months is around 2.62%, less than GILD's 2.82% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
RPRX Royalty Pharma plc | 2.62% | 3.29% | 2.85% | 1.92% | 1.71% | 0.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GILD Gilead Sciences, Inc. | 2.82% | 3.33% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% |
Drawdowns
RPRX vs. GILD - Drawdown Comparison
The maximum RPRX drawdown since its inception was -49.68%, smaller than the maximum GILD drawdown of -70.82%. Use the drawdown chart below to compare losses from any high point for RPRX and GILD.
Loading data...
Volatility
RPRX vs. GILD - Volatility Comparison
The current volatility for Royalty Pharma plc (RPRX) is 7.62%, while Gilead Sciences, Inc. (GILD) has a volatility of 12.15%. This indicates that RPRX experiences smaller price fluctuations and is considered to be less risky than GILD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
RPRX vs. GILD - Financials Comparison
This section allows you to compare key financial metrics between Royalty Pharma plc and Gilead Sciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RPRX vs. GILD - Profitability Comparison
RPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Royalty Pharma plc reported a gross profit of 568.25M and revenue of 568.25M. Therefore, the gross margin over that period was 100.0%.
GILD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Gilead Sciences, Inc. reported a gross profit of 5.13B and revenue of 6.67B. Therefore, the gross margin over that period was 76.9%.
RPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Royalty Pharma plc reported an operating income of 534.18M and revenue of 568.25M, resulting in an operating margin of 94.0%.
GILD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Gilead Sciences, Inc. reported an operating income of 2.24B and revenue of 6.67B, resulting in an operating margin of 33.6%.
RPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Royalty Pharma plc reported a net income of 238.35M and revenue of 568.25M, resulting in a net margin of 41.9%.
GILD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Gilead Sciences, Inc. reported a net income of 1.32B and revenue of 6.67B, resulting in a net margin of 19.7%.